Video: Marty Tenenbaum Speaks at Microsoft Research

Cancer Commons founder Marty Tenenbaum, PhD, recently visited Microsoft’s Richmond, CA, office to give a presentation entitled “How to Beat Cancer.”

Because of “a convergence of recent developments in genomics, big data informatics, social networks, and personalized medicine that is transforming the landscape of cancer research and treatment,” Marty says, “we are now on the threshold of being able to give each individual the knowledge, resources, and tools needed to successfully treat the one disease that matters most to them.”

Watch the complete presentation at the Microsoft Research site.


Nature Reviews Clinical Oncology Publishes Paper by Marty Tenenbaum

Today the journal Nature Reviews Clinical Oncology published a paper written by Cancer Commons founder Marty Tenenbaum and co-author Jeff Shrager. The piece discusses the concept of Rapid Learning Precision Oncology. In this approach, every patient receives the best available treatment for them, based on the specifics of their diagnosis. Then the outcomes (e.g., tumor shrinkage, side effects, quality of life, etc.) are used to support and refine the treatment model on which patients’ treatment decisions are based. Tenenbaum and Shrager review the Rapid Learning Precision Oncology approach and the many challenges to its implementation.

Read the article: Rapid learning for precision oncology. Nature Reviews Clinical Oncology. Jan 21, 2014. doi: 10.1038/nrclinonc.2013.244

Please contact us if you are interested in a pdf of the paper.


Cancer Commons Partners with the Melanoma Research Foundation to Launch Online Patient Registry

Today Cancer Commons and the Melanoma Research Foundation announce an online patient registry to advance research for a cure.

For Immediate Release: January 17, 2014

 

The Melanoma Research Foundation and Cancer Commons partner to launch online patient registry to advance research for a cure

Donate Your Data (DYD) is the first platform to collect open-access information that will be made available to patients, physicians and researchers

Washington, DC, and Palo Alto, California, January 17, 2014 – The Melanoma Research Foundation (MRF) and Cancer Commons today announce the launch of the Donate Your Data (DYD) Program, an online registry for melanoma patients and survivors. DYD encourages patients to anonymously share their cancer experiences to advance research and, in return, inform their own clinical care.

Melanoma is one of the fastest growing cancers. With a 1 in 50 lifetime risk of developing melanoma, nearly 77,000 Americans were expected to be diagnosed with the disease in 2013, resulting in over 9,400 deaths.

Through DYD, each melanoma patient records and updates personal disease characteristics in a private, secure online profile. Entries capture stage, treatments, molecular test results, side effects, and treatment responses. All data will be made freely available in de-identified form, giving doctors, researchers, and patients themselves an unprecedented resource to determine the best approaches to melanoma care, according to each patient’s unique clinical history.

“DYD aims to collect data from at least 10% of the approximately 1 million melanoma patients and survivors in the U.S., and even more worldwide,” says Shelby Moneer, Education Program Manager at the MRF. “Our partnership with Cancer Commons is an exciting new facet of our commitment to providing patient resources and supporting research into effective treatments and eventually, a cure for this disease.”

Continue reading…


Marty Tenenbaum to Lead Panel Discussion at 2014 Personalized Medicine World Conference

Cancer Commons founder Marty Tenenbaum will lead a panel discussion at the 2014 Personalized Medicine World Conference (PMWC) on Jan 27. The discussion, entitled, “PM in Oncology Today: Making It Work for Patients, Clinicians, Researchers, and Industry,” will also feature George Demetri of Dana-Farber/Harvard Cancer Center, Vincent A. Miller of Foundation Medicine, lung cancer survivor Neil Schiffman, and Edgar Staren of CTCA Medicine and Science. Their diverse perspectives will ignite insightful discussion regarding the current use and future promise of personalized medicine in cancer.

The 6th annual PMWC conference in Silicon Valley runs Jan 27–28. It brings together leaders from multiple sectors—including business, government, healthcare-delivery, research and technology—to learn from each other and further the field of personalized medicine. Dr. Tenenbaum’s panel discussion is at 11 am on the main-stage. General registration is available through Jan 24.


Marty Tenenbaum to Speak at Monte Jade Forum on Personalized Medicine

Cancer Commons founder Marty Tenenbaum, PhD, will speak tomorrow at the Monte Jade Forum, an event organized by the Monte Jade Science and Technology Association (West Coast). The Forum is entitled Personalized Precision Medicine – What does it mean for the cancer patient? Dr. Tenenbaum will join oncologist Edmund Tai, MD, in a discussion of how personalized medicine, or “precision oncology,” can help cancer patients. Dr. Tenenbaum will discuss Cancer Commons as “an emerging patient-led movement that empowers each patient and their care team to get the best available knowledge for beating their cancer, and to update that knowledge in real time based on each patient’s outcome.”

The Forum takes place tomorrow, Nov 6, 2013, at 7:00pm at ITRI International in San Jose, CA. Registration is available online, and non-members can register for $20.


Listen: Marty Tenenbaum Featured in New Mendelspod Podcast

Cancer Commons founder Dr. Marty Tenenbaum is featured in a new podcast from Mendelspod. In the podcast, entitled “4 Reasons Clinical Trials Don’t Work,” Dr. Tenenbaum outlines the shortcomings of the current state of the clinical trial system, and offer solutions for improvement. Cancer Commons is key to his vision of a revamped cancer research system that focuses on individual cancer patients to find answers faster. Listen on the website, or download the podcast to listen later.


"How to Beat Cancer:" Marty Tenenbaum to Speak at Silicom Ventures' Monthly Meeting

Cancer Commons founder Dr. Marty Tenenbaum will be speaking tomorrow at the monthly meeting of Silicom Ventures, a Silicon Valley-based investment forum. Dr. Tenenbaum will discuss his vision for a personalized approach to oncology, offering solutions that could help answer these questions:

-Which are the best drugs and trials for me?
-How can I get timely and affordable access to the latest investigational drugs?
-How can we slash the time and cost of drug development so that the economics work for therapies that target small subsets of patients?
-Can cancer research be funded, one patient at a time?

The meeting takes place tomorrow, Sep. 10, in Santa Clara, CA. Guest registration is available on the event page.


Nature Biotechnology Publishes Cancer Megafund Article by Marty Tenenbaum

On June 10, the journal Nature Biotechnology published an article written by Cancer Commons founder Marty Tenenbaum. The piece addresses a previously published article that proposes a megafund approach to finance biomedical research. According to Dr. Tenenenbaum, the megafund approach will not only reduce risk for investors, but will also “slash the time, cost and risk of drug development by radically rethinking development processes, business models and organizational structures, and requiring the open sharing of data, knowledge and resources across portfolio projects. The resulting impact on productivity, risk and new therapeutic opportunities could potentially dwarf the returns from financial engineering.”

Read Dr. Tenenbaum’s article here: The Cancer Megafund: A Catalyst for Disruptive Innovation. Nature Biotechnology 31, 491-492 (2013) doi:10.1038/nbt.2605.


Watch and Read: Dr. Tenenbaum on The Impact of Personalized Medicine

On May 7, Cancer Commons founder Marty Tenenbaum hosted a panel in The Scientists three-part webinar series Decoding DNA: New Twists and Turns. A summary of the webinar was featured in the June issue of The ScientistThe Scientist June 2013 JMT Webinar. Watch Dr. Tenenbaum and other experts discuss The Impact of Personalized Medicine:

The Impact of Personalized Medicine from thescientistllc on Vimeo:

“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.

Panelists:

Jay M. (‘Marty’) Tenenbaum, Ph.D., Chairman and Founder, Cancer Commons

Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program

Geoffrey S. Ginsburg, MD, PhD, Director, Genomic Medicine, Duke Institute for Genome Sciences & Policy Executive Director, Center for Personalized Medicine Duke Medicine, Professor of Medicine and Pathology Duke University Medical Center

Abhijit ‘Ron’ Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson”